The Roles of Alternative Splicing in Tumor-immune Cell Interactions-Reference-Cited by-同舟云学术

The Roles of Alternative Splicing in Tumor-immune Cell Interactions

Published:2020-11-02 Issue:10 Volume:20 Page:729-740
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Wang Yue¹,Zhang Honglei²,Jiao Baowei²,Nie Jianyun¹,Li Xiyin¹,Wang Wenhuan¹,Wang Hairui¹

Affiliation:

1. Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China

2. State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China

Abstract

Alternative splicing (AS) plays a significant role in the hallmarks of cancer and can provide neoantigens for immunotherapy. Here, we summarize recent advances in immune system associated tumor specific-antigens (TSAs) produced by AS. We further discuss the regulating mechanisms involved in AS-mediated innate and adaptive immune responses and the anti-tumoral and protumoral roles in different types of cancer. For example, ULBP1_RI, MLL5Δ21spe, NKp44-1Δ5, MHC-IΔ7, CD200SΔ1, 2, PVR α/β/γ/δ and IL-33 variants 1/2/3 act as regulators in solid tumors and IPAK4-L and, FOXP1ΔN100 exhibit functions in hematological cancers.

Funder

National Natural Science Foundation of China

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference113 articles.

1. Tran E.; Robbins P.F.; Rosenberg S.A.; Final common pathway’ of human cancer immunotherapy: Targeting random somatic mutations. Nat Immunol 2017,18(3),255-262

2. Paucek R.D.; Baltimore D.; Li G.; The cellular immunotherapy revolution: arming the immune system for precision therapy. Trends Immunol 2019,40(4),292-309

3. Rapoport A.P.; Stadtmauer E.A.; Binder-Scholl G.K.; Goloubeva O.; Vogl D.T.; Lacey S.F.; Badros A.Z.; Garfall A.; Weiss B.; Finklestein J.; Kulikovskaya I.; Sinha S.K.; Kronsberg S.; Gupta M.; Bond S.; Melchiori L.; Brewer J.E.; Bennett A.D.; Gerry A.B.; Pumphrey N.J.; Williams D.; Tayton-Martin H.K.; Ribeiro L.; Holdich T.; Yanovich S.; Hardy N.; Yared J.; Kerr N.; Philip S.; Westphal S.; Siegel D.L.; Levine B.L.; Jakobsen B.K.; Kalos M.; June C.H.; NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015,21(8),914-921

4. Robbins P.F.; Morgan R.A.; Feldman S.A.; Yang J.C.; Sherry R.M.; Dudley M.E.; Wunderlich J.R.; Nahvi A.V.; Helman L.J.; Mackall C.L.; Kammula U.S.; Hughes M.S.; Restifo N.P.; Raffeld M.; Lee C.C.; Levy C.L.; Li Y.F.; El-Gamil M.; Schwarz S.L.; Laurencot C.; Rosenberg S.A.; Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011,29(7),917-924

5. Ott P.A.; Hu Z.; Keskin D.B.; Shukla S.A.; Sun J.; Bozym D.J.; Zhang W.; Luoma A.; Giobbie-Hurder A.; Peter L.; Chen C.; Olive O.; Carter T.A.; Li S.; Lieb D.J.; Eisenhaure T.; Gjini E.; Stevens J.; Lane W.J.; Javeri I.; Nellaiappan K.; Salazar A.M.; Daley H.; Seaman M.; Buchbinder E.I.; Yoon C.H.; Harden M.; Lennon N.; Gabriel S.; Rodig S.J.; Barouch D.H.; Aster J.C.; Getz G.; Wucherpfennig K.; Neuberg D.; Ritz J.; Lander E.S.; Fritsch E.F.; Hacohen N.; Wu C.J.; An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017,547(7662),217-221

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens;Vaccines;2024-06-27

2. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation;PeerJ;2023-07-17

3. Neoantigens: promising targets for cancer therapy;Signal Transduction and Targeted Therapy;2023-01-06

4. The Role of Soluble Immune Checkpoints in Cancer Immunotherapy;Handbook of Cancer and Immunology;2023

5. Novel prognostic model predicts overall survival in colon cancer based on RNA splicing regulation gene expression;Cancer Science;2022-08-16